Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1992 Aug;36(8):1766–1769. doi: 10.1128/aac.36.8.1766

Analysis of vancomycin time-kill studies with Staphylococcus species by using a curve stripping program to describe the relationship between concentration and pharmacodynamic response.

B H Ackerman 1, A M Vannier 1, E B Eudy 1
PMCID: PMC192044  PMID: 1416862

Abstract

Mono- and biexponential killing curves for vancomycin over a 2- to 50-micrograms/ml concentration range were generated for 11 Staphylococcus aureus isolates and 12 coagulase-negative Staphylococcus species in the logarithmic phase of growth. Nonlinear least-squares regression of the initial growth rate and disappearance were not significantly different for lower or higher concentrations of vancomycin in broth.

Full text

PDF
1766

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Ackerman B. H. Evaluation of three methods for determining initial vancomycin doses. DICP. 1989 Feb;23(2):123–128. doi: 10.1177/106002808902300203. [DOI] [PubMed] [Google Scholar]
  2. Barr J. G., Smyth E. T., Hogg G. M. In vitro antimicrobial activity of imipenem in combination with vancomycin or teicoplanin against Staphylococcus aureus and Staphylococcus epidermidis. Eur J Clin Microbiol Infect Dis. 1990 Nov;9(11):804–809. doi: 10.1007/BF01967378. [DOI] [PubMed] [Google Scholar]
  3. Bartoloni A., Colao M. G., Orsi A., Dei R., Giganti E., Parenti F. In-vitro activity of vancomycin, teicoplanin, daptomycin, ramoplanin, MDL 62873 and other agents against staphylococci, enterococci and Clostridium difficile. J Antimicrob Chemother. 1990 Nov;26(5):627–633. doi: 10.1093/jac/26.5.627. [DOI] [PubMed] [Google Scholar]
  4. Biavasco F., Giovanetti E., Montanari M. P., Lupidi R., Varaldo P. E. Development of in-vitro resistance to glycopeptide antibiotics: assessment in staphylococci of different species. J Antimicrob Chemother. 1991 Jan;27(1):71–79. doi: 10.1093/jac/27.1.71. [DOI] [PubMed] [Google Scholar]
  5. Bingen E., Lambert-Zechovsky N., Leclercq R., Doit C., Mariani-Kurkdjian P. Bactericidal activity of vancomycin, daptomycin, ampicillin and aminoglycosides against vancomycin-resistant Enterococcus faecium. J Antimicrob Chemother. 1990 Nov;26(5):619–626. doi: 10.1093/jac/26.5.619. [DOI] [PubMed] [Google Scholar]
  6. Brown R. D., Manno J. E. ESTRIP, a BASIC computer program for obtaining initial polyexponential parameter estimates. J Pharm Sci. 1978 Dec;67(12):1687–1691. doi: 10.1002/jps.2600671214. [DOI] [PubMed] [Google Scholar]
  7. Carret G., Flandrois J. P., Lobry J. R. Biphasic kinetics of bacterial killing by quinolones. J Antimicrob Chemother. 1991 Mar;27(3):319–327. doi: 10.1093/jac/27.3.319. [DOI] [PubMed] [Google Scholar]
  8. Chambers H. F., Kennedy S. Effects of dosage, peak and trough concentrations in serum, protein binding, and bactericidal rate on efficacy of teicoplanin in a rabbit model of endocarditis. Antimicrob Agents Chemother. 1990 Apr;34(4):510–514. doi: 10.1128/aac.34.4.510. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Cooper M. A., Jin Y. F., Ashby J. P., Andrews J. M., Wise R. In-vitro comparison of the post-antibiotic effect of vancomycin and teicoplanin. J Antimicrob Chemother. 1990 Aug;26(2):203–207. doi: 10.1093/jac/26.2.203. [DOI] [PubMed] [Google Scholar]
  10. Garrison M. W., Vance-Bryan K., Larson T. A., Toscano J. P., Rotschafer J. C. Assessment of effects of protein binding on daptomycin and vancomycin killing of Staphylococcus aureus by using an in vitro pharmacodynamic model. Antimicrob Agents Chemother. 1990 Oct;34(10):1925–1931. doi: 10.1128/aac.34.10.1925. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Geraci J. E., Hermans P. E. Vancomycin. Mayo Clin Proc. 1983 Feb;58(2):88–91. [PubMed] [Google Scholar]
  12. Gilbert D. N., Wood C. A., Kimbrough R. C. Failure of treatment with teicoplanin at 6 milligrams/kilogram/day in patients with Staphylococcus aureus intravascular infection. The Infectious Diseases Consortium of Oregon. Antimicrob Agents Chemother. 1991 Jan;35(1):79–87. doi: 10.1128/aac.35.1.79. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Goldstein F. W., Coutrot A., Sieffer A., Acar J. F. Percentages and distributions of teicoplanin- and vancomycin-resistant strains among coagulase-negative staphylococci. Antimicrob Agents Chemother. 1990 May;34(5):899–900. doi: 10.1128/aac.34.5.899. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Greenberg R. N., Benes C. A. Time-kill studies with oxacillin, vancomycin, and teicoplanin versus Staphylococcus aureus. J Infect Dis. 1990 May;161(5):1036–1037. doi: 10.1093/infdis/161.5.1036. [DOI] [PubMed] [Google Scholar]
  15. Hurst A. K., Yoshinaga M. A., Mitani G. H., Foo K. A., Jelliffe R. W., Harrison E. C. Application of a Bayesian method to monitor and adjust vancomycin dosage regimens. Antimicrob Agents Chemother. 1990 Jun;34(6):1165–1171. doi: 10.1128/aac.34.6.1165. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Krogstad D. J., Moellering R. C., Jr, Greenblatt D. J. Single-dose kinetics of intravenous vancomycin. J Clin Pharmacol. 1980 Apr;20(4 Pt 1):197–201. doi: 10.1002/j.1552-4604.1980.tb01696.x. [DOI] [PubMed] [Google Scholar]
  17. Laskarzewski P. M., Weiner D. L., Ott L. A simulation study of parameter estimation in the one and two compartment models. J Pharmacokinet Biopharm. 1982 Jun;10(3):317–334. doi: 10.1007/BF01059264. [DOI] [PubMed] [Google Scholar]
  18. Levett P. N. Time-dependent killing of Clostridium difficile by metronidazole and vancomycin. J Antimicrob Chemother. 1991 Jan;27(1):55–62. doi: 10.1093/jac/27.1.55. [DOI] [PubMed] [Google Scholar]
  19. Levine D. P., Fromm B. S., Reddy B. R. Slow response to vancomycin or vancomycin plus rifampin in methicillin-resistant Staphylococcus aureus endocarditis. Ann Intern Med. 1991 Nov 1;115(9):674–680. doi: 10.7326/0003-4819-115-9-674. [DOI] [PubMed] [Google Scholar]
  20. Matzke G. R., McGory R. W., Halstenson C. E., Keane W. F. Pharmacokinetics of vancomycin in patients with various degrees of renal function. Antimicrob Agents Chemother. 1984 Apr;25(4):433–437. doi: 10.1128/aac.25.4.433. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Maugein J., Pellegrin J. L., Brossard G., Fourche J., Leng B., Reiffers J. In vitro activities of vancomycin and teicoplanin against coagulase-negative staphylococci isolated from neutropenic patients. Antimicrob Agents Chemother. 1990 May;34(5):901–903. doi: 10.1128/aac.34.5.901. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Peetermans W. E., Hoogeterp J. J., Hazekamp-van Dokkum A. M., van den Broek P., Mattie H. Antistaphylococcal activities of teicoplanin and vancomycin in vitro and in an experimental infection. Antimicrob Agents Chemother. 1990 Oct;34(10):1869–1874. doi: 10.1128/aac.34.10.1869. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Pfaller M. A., Krogstad D. J., Granich G. G., Murray P. R. Laboratory evaluation of five assay methods for vancomycin: bioassay, high-pressure liquid chromatography, fluorescence polarization immunoassay, radioimmunoassay, and fluorescence immunoassay. J Clin Microbiol. 1984 Sep;20(3):311–316. doi: 10.1128/jcm.20.3.311-316.1984. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Van der Auwera P., Aoun M., Meunier F. Randomized study of vancomycin versus teicoplanin for the treatment of gram-positive bacterial infections in immunocompromised hosts. Antimicrob Agents Chemother. 1991 Mar;35(3):451–457. doi: 10.1128/aac.35.3.451. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Van der Auwera P., Prinz G., Petrikkos G. Activity of intracellular antibiotics. Infection. 1991;19 (Suppl 4):S216–S223. doi: 10.1007/BF01644037. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES